Vendor review
Shanghai Wibson Biotechnology WBS reviews
Shanghai Wibson Biotechnology WBS reviews from 61 independent lab tests (Retatrutide, Tirzepatide and Tesamorelin): grade A, purity and fill accuracy. Is Shanghai Wibson Biotechnology WBS legit? See what its vials showed.
What the lab tests show
61 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Sep 25, 2026 | TB-500 | 99.9 % | 9.99 mg of 10 mg (0 %) | Pass | View |
| Sep 24, 2026 | GHK-Cu | 99.7 % | 87.7 mg of 100 mg (-12 %) | Pass | View |
| Sep 18, 2026 | Tesamorelin | 99.9 % | 7.46 mg of 10 mg (-25 %) | Pass | View |
| Sep 15, 2026 | BPC-157 | 78 % | 9.29 mg of 10 mg (-7 %) | Pass | View |
| Sep 15, 2026 | Retatrutide | 99.9 % | 19.5 mg of 10 mg (95 %) | Pass | View |
| Sep 8, 2026 | Retatrutide | 99.9 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Aug 26, 2026 | Tirzepatide | 99.9 % | 19.6 mg of 20 mg (-2 %) | Pass | View |
| Aug 12, 2026 | Retatrutide | 99.5 % | 14.5 mg of 10 mg (45 %) | Pass | View |
| Aug 4, 2026 | Tesamorelin | 99.9 % | 21.3 mg of 20 mg (7 %) | Pass | View |
| Aug 4, 2026 | Retatrutide | 99.9 % | 27.8 mg of 30 mg (-7 %) | Pass | View |
| Aug 4, 2026 | Retatrutide | 99.9 % | 56.4 mg of 60 mg (-6 %) | Pass | View |
| Aug 4, 2026 | Ipamorelin | 99.7 % | 9.75 mg of 10 mg (-3 %) | Pass | View |
| Jul 23, 2026 | BPC-157 | 81.5 % | 8.74 mg of 10 mg (-13 %) | Pass | View |
| Jul 23, 2026 | GHK-Cu | 99.9 % | 73.7 mg of 100 mg (-26 %) | Pass | View |
| Jul 21, 2026 | Tesamorelin | 99.9 % | 8.64 mg of 10 mg (-14 %) | Pass | View |
| Jul 20, 2026 | Tirzepatide | 99.9 % | 9.17 mg of 10 mg (-8 %) | Pass | View |
| Jul 17, 2026 | Retatrutide | 99.9 % | 9.26 mg of 10 mg (-7 %) | Pass | View |
| Jul 17, 2026 | Ipamorelin | 99.7 % | 9.96 mg of 10 mg (0 %) | Pass | View |
| Jul 14, 2026 | BPC-157 | 99.6 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Jul 13, 2026 | Tesamorelin | 98.2 % | 10.6 mg of 10 mg (6 %) | Pass | View |
| Jul 13, 2026 | Ipamorelin | 99.1 % | 7.89 mg of 5 mg (58 %) | Pass | View |
| Jul 13, 2026 | Retatrutide | 99.9 % | 11.2 mg of 10 mg (12 %) | Pass | View |
| Jul 1, 2026 | Retatrutide | 99.9 % | 22 mg of 20 mg (10 %) | Pass | View |
| Jul 1, 2026 | BPC-157 | 99.9 % | 8.82 mg of 10 mg (-12 %) | Pass | View |
| Jul 1, 2026 | TB-500 | 98.4 % | 9.67 mg of 10 mg (-3 %) | Pass | View |
| Jun 17, 2026 | Retatrutide | 99.9 % | 20.4 mg of 20 mg (2 %) | Pass | View |
| Jun 16, 2026 | Tesamorelin | 20 mg | Fail | View | |
| Jun 16, 2026 | Cagrilintide | 99.6 % | 5.7 mg of 5 mg (14 %) | Pass | View |
| Jun 12, 2026 | TB-500 | 99.2 % | 8.83 mg of 10 mg (-12 %) | Pass | View |
| Jun 12, 2026 | Tirzepatide | 99.9 % | 49.2 mg of 50 mg (-2 %) | Pass | View |
| Jun 5, 2026 | Retatrutide | 99.9 % | 13.6 mg of 15 mg (-9 %) | Pass | View |
| Jun 2, 2026 | Retatrutide | 99.9 % | 9.1 mg of 10 mg (-9 %) | Pass | View |
| Jun 1, 2026 | Retatrutide | 99.8 % | 20.2 mg of 20 mg (1 %) | Pass | View |
| May 19, 2026 | Tirzepatide | 99.9 % | 29.5 mg of 30 mg (-2 %) | Pass | View |
| May 18, 2026 | Retatrutide | 99.8 % | 56.2 mg of 60 mg (-6 %) | Pass | View |
| May 11, 2026 | Tirzepatide | 60 mg | View | ||
| May 8, 2026 | Tirzepatide | 99.9 % | 59.4 mg of 60 mg (-1 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.9 % | 9.63 mg of 10 mg (-4 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.9 % | 9.98 mg of 20 mg (-50 %) | Pass | View |
| Apr 23, 2026 | Retatrutide | 99.9 % | 10.7 mg of 10 mg (7 %) | Pass | View |
| Mar 21, 2026 | BPC-157 | 99.8 % | 12.5 mg of 10 mg (25 %) | Pass | View |
| Mar 18, 2026 | GHK-Cu | 99.9 % | 81.9 mg of 100 mg (-18 %) | Pass | View |
| Mar 6, 2026 | Retatrutide | 99.3 % | 29.9 mg of 30 mg (0 %) | Pass | View |
| Mar 6, 2026 | BPC-157 | 99.9 % | 9.33 mg of 10 mg (-7 %) | Pass | View |
| Mar 6, 2026 | Tirzepatide | 99.9 % | 51.1 mg of 60 mg (-15 %) | Pass | View |
| Mar 2, 2026 | Tesamorelin | 99.9 % | 11 mg of 10 mg (10 %) | Pass | View |
| Mar 2, 2026 | Retatrutide | 99.9 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Feb 20, 2026 | GHK-Cu | 99.7 % | 43.6 mg of 50 mg (-13 %) | Pass | View |
| Feb 20, 2026 | Retatrutide | 99.7 % | 10.8 mg of 10 mg (8 %) | Pass | View |
| Feb 18, 2026 | GHK-Cu | 99.9 % | 57.8 mg of 100 mg (-42 %) | Pass | View |
| Jan 26, 2026 | Ipamorelin | 99.9 % | 5.12 mg of 5 mg (2 %) | Pass | View |
| Jan 22, 2026 | Retatrutide | 99.8 % | 10.9 mg of 10 mg (9 %) | Pass | View |
| Jan 19, 2026 | Tesamorelin | 98.99 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Jan 19, 2026 | Retatrutide | 99.95 % | 27.8 mg of 30 mg (-7 %) | Pass | View |
| Jan 19, 2026 | Tirzepatide | 99.82 % | 33.5 mg of 30 mg (12 %) | Pass | View |
| Jan 19, 2026 | Cagrilintide | 96.16 % | 4.84 mg of 5 mg (-3 %) | Pass | View |
| Aug 28, 2025 | Tirzepatide | 99.95 % | 32.5 mg of 30 mg (8 %) | Pass | View |
| Aug 6, 2025 | Tirzepatide | 99.89 % | 33.85 mg of 30 mg (13 %) | Pass | View |
| Aug 6, 2025 | Cagrilintide | 97.73 % | 5.7 mg of 5 mg (14 %) | Pass | View |
| Jul 8, 2025 | Tirzepatide | 99.976 % | 34.82 mg of 30 mg (16 %) | Pass | View |
What Shanghai Wibson Biotechnology WBS sells
No current listings on record.
About Shanghai Wibson Biotechnology WBS
Finnrick has tested 61 samples from Shanghai Wibson Biotechnology WBS across 8 products.